Lexeo Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows (unaudited)
Condensed Statements of Cash Flows
(Unaudited, in thousands)
| Three Months Ended March 31, | |||
|---|---|---|---|
| 2026 · 2025 | |||
| Cash flows from operating activities: | |||
| Net loss | $(20,196) | $(32,656) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Reduction in the carrying amount of ROU assets, operating | 393 | 361 | |
| Reduction in the carrying amount of ROU assets, finance | 80 | 80 | |
| Stock-based compensation expense | 2,755 | 3,697 | |
| Depreciation and amortization expense | 73 | 60 | |
| Amortization of premium (accretion of discount) on investments in U.S. Treasury securities | (42) | 12 | |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | (1,119) | (362) | |
| Accounts payable | (1,596) | 5,143 | |
| Accrued expenses and other current liabilities | (1,092) | 2,315 | |
| Lease liabilities, operating | (402) | (357) | |
| Lease liabilities, finance | 2 | (9) | |
| Net cash used in operating activities | (21,144) | (21,716) | |
| Cash flows from investing activities: | |||
| Purchase of property and equipment | (35) | - | |
| Proceeds from sales or maturities of investments | 27,495 | 15,600 | |
| Net cash provided by investing activities | 27,460 | 15,600 | |
| Cash flows from financing activities: | |||
| Proceeds from exercise of common warrants | 2,446 | - | |
| Proceeds from exercise of stock options | 9 | - | |
| Payments on finance leases | (121) | (159) | |
| Proceeds from common stock issuances under 2023 ESPP | 143 | 170 | |
| Third-party commissions and offering costs incurred upon October 2025 Financing Transactions | (25) | - | |
| Net cash provided by financing activities | 2,452 | 11 | |
| Net change in cash, cash equivalents and restricted cash | 8,768 | (6,105) | |
| Cash, cash equivalents and restricted cash at beginning of period | 66,248 | 38,266 | |
| Cash, cash equivalents and restricted cash at end of period | $75,016 | $32,161 | |
| Supplemental disclosure of non-cash activities | |||
| Unrealized gain (loss) on investments | $(330) | $49 | |
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase | $1 | $13 | |
| Unpaid offering costs included in accounts payable and accrued expenses | $75 | $478 | |
| Property and equipment purchased in the prior period and paid in the current period, net of property and equipment purchased in the current period included in accounts payable | $ | - | $77 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.